Our findings not only suggest that SMARCC2 may serve as a prognostic indicator in glioblastoma patients but also raise the possibility of the clinical benefit of PI3K–AKT inhibition in patients with SMARCC2-low or null cancers. This evidence concerns the gene AKT1 and cancer.